13 April 2021
Apollon Formularies PLC
(“Apollon” or the “Firm”)
ADMISSION TO TRADING ON AQSE GROWTH MARKET AND FIRST DAY OF DEALINGS
CONSENT FROM APOLLON LIMITED SHAREHOLDERS
Apollon Formularies PLC (AQSE: APOL) is happy to announce that admission of the Firm’s atypical shares to buying and selling on AQSE Development Market (“Admission”) will happen and dealings will start at 8.00 am GMT at present, Tuesday 13 April 2021, below the ticker “APOL” (ISIN: IM00BJ0LRD77).
Profitable £2.5 million fundraising at 5p which was oversubscribed. Peterhouse acted as company dealer
Apollon’s Jamaican affiliate has a federal licensing framework that permits it to function a completely built-in seed to affected person enterprise
Apollon’s Jamaican affiliate’s processing laboratory based mostly in Negril, Jamaica is ready to produce excessive volumes of full spectrum medical hashish oil, utilizing each excessive and low THC hashish plant materials
Apollon’s Jamaican affiliate’s R&D licence permits its medical group to undertake full spectrum, medically supervised remedies and conduct medical trials as authorized by the Jamaican Ministry of Well being
Proceeds can be used to, amongst different issues, scale up operations, establish worldwide prospects for its prime quality oils, commercialise growth of its 3D-printer for manufacturing of medical hashish sublingual, oral and suppository merchandise, and proceed its R&D in an effort to develop the Apollon product line vary of each excessive and low THC oils and merchandise, broaden cultivation and processing of its formulations and improve capability and worldwide export for its medical hashish remedies
The Firm notes that the Distributors of Apollon Restricted, voted their shares 100% (excluding these shares already owned by the Firm) in favour of the Supply.
Dr Stephen Barnhill, CEO of Apollon Formularies Plc, says:
“As we speak we achieved an vital milestone and I’m happy with the group and the work that has been achieved to get us right here. With a full itemizing on the AQSE Development Market, we are going to now set about to scale up our already spectacular operation.
“Apollon at present holds a novel place as one of many few listed European firms in a position to undertake medically supervised remedies inclusive of utilising THC to permit for drug discovery and the event of further formulations so as to add to our already profitable product line vary. This itemizing in London affords traders the chance to be part of a full spectrum medical hashish firm because it strikes to implement its worldwide development technique. That is an thrilling time for our Firm, in addition to your complete medical hashish house throughout the UK and Europe, and we stay up for updating the market as we proceed to ship upon our technique.”
Apollon Formularies plc is a world medicinal hashish pharmaceutical firm. Apollon Formularies Jamaica Restricted (“AFJ”) is the principal entity with which Apollon has an curiosity. AFJ is a authorities licenced medicinal hashish firm included in Jamaica and is licensed and authorized to domesticate, course of, carry out analysis and growth for, and promote medical hashish therapeutic merchandise.
AFJ is at present producing pharmaceutical, nutraceutical, and different medical hashish associated merchandise, together with 3D printed sublingual, suppositories and capsules. It was established to advance the present important industrial alternatives within the authorized medical hashish markets globally.
AFJ operates on the Federal degree in Jamaica and holds a collection of licences that permits it to be a completely operational, vertically leveraged medical hashish enterprise
AFJ’s cultivation licence permits it to develop and develop strains of hashish for medicinal makes use of
AFJ’s Processing Laboratory relies in Negril, Jamaica, and is ready to produce full spectrum medical hashish oil, which is inclusive of THC
AFJ’s R&D licence permits it to undertake initiatives for drug discovery utilizing THC and different cannabinoids to develop a variety of merchandise which can be backed by medical knowledge
AFJ’s science and medical professionals have developed and use proprietary synthetic intelligence to establish compounds and develop formations that may be productized, examined, clinically trialed, after which used on varied sicknesses below medical supervision
AFJ owns and operates a therapeutic medical hashish dispensary onsite in Jamaica
AFJ has created and/or obtained, recognized, developed, and commercialised a number of proprietary hybrid medical hashish pharmaceutical strains, know-how, formulations, and therapy merchandise
AFJ’s vertically licenced, full spectrum medical hashish framework provides the Firm the unrivalled capability to carry out medically supervised remedies
The Administrators of the Firm settle for accountability for the contents of this announcement.
– Ends –
For extra info please contact:
Tel: +44 207 907 9314
Stene Jacobs email@example.com
Peterhouse Capital Restricted (Company Adviser)
Tel: +44 207 220 9795
Man Miller firstname.lastname@example.org
Blytheweigh (Monetary PR/IR-London)
Tel: +44 207 138 3204
Tim Blythe email@example.com
Megan Ray firstname.lastname@example.org